BCR-ABL 测试市场：规模、份额、法规、按细分市场划分的报销、到 2033 年的预测

白血病是一组影响血液和骨髓的异质性癌症。 两种常见的亚型是淋巴球白血病和髓细胞白血病，它们分别起源于淋巴球和粒细胞。 白血病可以快速进展（急性）或缓慢进展（慢性），是 20 岁以下儿童和年轻人癌症死亡的主要原因。 白血病没有标准的分期系统，白血病分为未经治疗、缓解或復发。

BCR-ABL，又称费城（Ph）染色体，是由22号染色体上的BCR基因和9号染色体上的ABL1基因相互易位形成的突变。 这种易位导致 BCR-ABL 融合基因产生融合蛋白（一种酪氨酸激□信号蛋白），该蛋白被组成型激活，导致不受控制的细胞分裂。

BCR-ABL 检测包括 BCR-ABL 原位杂交 (ISH)、BCR-ABL 核酸扩增 (NAAT)、BCR-ABL 新一代定序 (NGS)、BCR-ABL 桑格定序和 BCR-ABL 包括焦磷酸测序和细胞遗传学测试。

本报告深入探讨了全球 BCR-ABL 测试市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响、区域和国家趋势等。

目录

目前BCR-ABL市场测试及竞争状况

• 对主要产业趋势的见解
• BCR-ABL 按细分市场测试总市场收入以及 2015 年至 2033 年的市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• BCR-ABL测试市场的SWOT分析
• BCR-ABL 测试市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BCR-ABL Tests market for the year 2020 and beyond. Leukemia is a heterogeneous group of cancers that affects the blood and bone marrow. Two common subtypes are lymphocytic leukemia's and myeloid leukemia's, which derive from lymphoid cells and myeloid cells, respectively. Leukemia can progress rapidly (acute), or slowly (chronic), and is the primary cause of deaths from cancer in children and young adults under the age of 20 years. There is no standard staging system for leukemia; the disease as described as untreated, in remission, or recurrent.

BCR-ABL is a mutation, also known as the Philadelphia (Ph) chromosome, which is formed by a reciprocal chromosomal translocation of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. This translocation results in a BCR-ABL fusion gene and production of a fusion protein - a tyrosine kinase signaling protein this is constitutively active, causing cells to divide uncontrollably.

The BCR-ABL tests include BCR-ABL In Situ Hybridization (ISH), BCR-ABL Nucleic Acid Amplification (NAATs), BCR-ABL Next Generation Sequencing (NGS), BCR-ABL Sanger Sequencing, BCR-ABL Pyrosequencing and Cytogenetics tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed BCR-ABL tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total BCR-ABL tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BCR-ABL Tests market.
• Competitive dynamics insights and trends provided for BCR-ABL Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Sysmex Corp, Bio-Techne Corp, Danaher Corp, Bio-Rad Laboratories Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Takara Bio Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BCR-ABL Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to-

• Understand the impact of COVID-19 on BCR-ABL Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BCR-ABL Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BCR-ABL Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific BCR-ABL Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable